Strategic partnerships Repertoire has active collaboration history with industry leaders (Genentech, Bristol Myers Squibb) and a strong pipeline around tolerizing vaccines and T cell targeted therapies, presenting cross-sell opportunities for partner-led programs and co-development discussions with large pharma.

Clinical expansion Recent leadership appointment of a new Chief Medical Officer and advancement of a TCR bispecific candidate toward the clinic indicate a move toward broader clinical execution, suggesting opportunities to engage on late-stage programs and potential advisory or trial-sponsorship roles.

Autoimmune focus Strategic emphasis on autoimmune diseases via tolerizing vaccines and DECODE platform insights aligns with high-value pharma needs in autoimmune indications, offering a path to interested targets, biomarker collaboration, and companion diagnostic opportunities.

Genentech/BMS synergies Existing and announced multi-year collaborations with Genentech and Bristol Myers Squibb imply readiness for additional licensing, milestone-based funding, or expansion into new indications, providing a blueprint for approaching similar large-cap partners.

Financing signal Significant funding milestones and a robust revenue stream position Repertoire as a credible partner for co-development funding, milestone-based deals, or upfront investments in new programs leveraging the DECODE platform and T cell repertoire insights.